Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab.
Irene Carrión-BarberàTarek Carlos Salman MonteSonia CastellFrancisco Castro-DomínguezFabiola OjedaJordi MonfortPublished in: European journal of rheumatology (2019)
Systemic lupus erythematosus (SLE) is characterized by a wide variety of manifestations and a difficult disease control in some patients. We present the case of a 51-year-old woman who presented with a flare of SLE including arthritis and pleuropericarditis that responded to neither leflunomide, methotrexate, nor high doses of prednisone. After initiating treatment with belimumab, the patient experienced a quick and notorious improvement. She remains stable to this day while continuing belimumab therapy.
Keyphrases
- systemic lupus erythematosus
- disease activity
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- rheumatoid arthritis
- peritoneal dialysis
- high dose
- prognostic factors
- case report
- stem cells
- patient reported outcomes
- low dose
- mesenchymal stem cells
- replacement therapy
- smoking cessation
- cell therapy